Doc.:	INS CMVG.CE/eng	Page	1 of 9	Rev.: 5	Date: 2019/11	
Doc.:		C Er uantit IgG a	nzyme ative/ antibo	e Imm qualit	Date: 2019/11	r the ination of lovirus
			. num	an 30		Sina
			- for "	in vitro"	diagnostic use onl	y -
				D	DIA.PRO Diagnostic Bio Via G. Carduc 20099 Sesto Sa (Milano) - Italy Phone +39 02 2700 Fax +39 02 443867 e-mail: info@diap	ci n° 27 n Giovanni 7 7161 771
						Code: CMVG.CE 96 Tests

CMV lgG

2 of 9

Rev.: 5

A. INTENDED USE

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgG antibodies to Cytomegalovirus in plasma and sera.

For "in vitro" diagnostic use only.

B. INTRODUCTION

Cytomegalovirus or CMV is an ubiquitous human pathogen, whose infection is particular prevalent among children and young adults. Infections by CMV continue to be an important health problem in certain patient populations, such as newborns, graft recipients of solid organs or bone marrow and AIDS patients. In these groups CMV is a major cause of morbidity and mortality.

The detection of virus-specific IgG and IgM antibodies is of great value in the diagnosis of acute/primary virus infections or reactivation of a latent one, in the absence of typical clinical symptoms. Asymptomatic infections usually happen for CMV in apparently healthy individuals, during pregnancy and several diseases as a coinfective agent.

C. PRINCIPLE OF THE TEST

Microplates are coated with native Cytomegalovirus antigens, highly purified by sucrose gradient centrifugation and inactivated.

The solid phase is first treated with the diluted sample and IgG to Cytomegalovirus are captured, if present, by the antigens.

After washing out all the other components of the sample, in the 2nd incubation bound anti Cytomegalovirus IgG are detected by the addition of polyclonal specific anti hIgG antibodies, labelled with peroxidase (HRP).

The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti Cytomegalovirus IgG antibodies present in the sample. A Calibration Curve, calibrated against the1st W.H.O international standard, makes possible a quantitative determination of the IgG antibody in the patient.

D. COMPONENTS

Each kit contains sufficient reagents to perform 96 tests.

1. Microplate: MICROPLATE

12 strips x 8 microwells coated with highly purified and UV inactivated Cytomegalovirus in presence of bovine proteins. Plates are sealed into a bag with desiccant. Allow the microplate to reach room temperature before opening; reseal unused strips in the bag with desiccant and store at 2..8°C.

2. Calibration Curve: CAL N° ... Ready to use and color coded standard curve derived from human plasma positive for CMV IgG and titrated on WHO standard (proposed International Standard) ranging:

- 4ml CAL 1 = 0 WHO IU/ml 4ml CAL 2 = 0,5 WHO IU/ml 2ml CAL 3 = 1 WHO IU/ml

- 2ml CAL 4 = 2 WHO IU/ml
- 2ml CAL 5 = 4 WHO IU/ml

4ml CAL 6 = 8 WHO IU/ml.

Standards are calibrated against W.H.O proposed international standard for anti-CMV IgG (document BS/95.1814).

It contains human serum proteins, 2% casein, 10 mM Triscitrate buffer pH 6.0 +/-0.1, 0.1% Tween 20, 0.09% Na-azide and 0.045% ProClin 300 as preservatives. Standards are blue colored.

3. Control Serum: CONTROL ...ml

Date: 2019/11

1 vial. Lyophilized. It contains fetal bovine serum proteins, human IgG antibodies to CMV calibrated at 2 WHO IU/ml <u>+</u>10%, 0.2 mg/ml gentamicine sulphate and 0.045% ProClin 300 as preservatives.

Note: The volume necessary to dissolve the content of the vial may vary from lot to lot. Please use the right volume reported on the label.

4. Wash buffer concentrate: WASHBUF 20X

1x60ml/bottle20x concentrated solution. Once diluted, the wash solution contains 10 mM phosphate buffer pH 7.0+/-0.2, 0.05% Tween 20 and 0.045% ProClin 300.

5. Enzyme conjugate : CONJ

2x8ml/vial.Ready to use and red colour coded. It contains Horseradish peroxidase conjugated polyclonal antibodies to human IgG, 5% BSA, 10 mM Tris buffer pH 6.8+/-0.1, 0.045% ProClin 300, 0.02% gentamicine sulphate as preservatives and 0.01% red alimentary dye.

6. Chromogen/Substrate: SUBS TMB

1x16ml/vial. It contains 50 mM citrate-phosphate buffer pH 3.5-3.8, 4% dimethylsulphoxide, 0.03% tetra-methyl-benzidine (or TMB) and 0.02% hydrogen peroxide (or H₂O₂).

Note: To be stored protected from light as sensitive to strong illumination.

7. Sulphuric Acid: H₂SO₄ 0.3 M

1x15ml/vial. It contains 0.3 M H₂SO₄ solution. Attention: Irritant (H315, H319; P280, P302+P352, P332+P313, P305+P351+P338, P337+P313, P362+P363).

8. Specimen Diluent: DILSPE

2x60ml/vial. It contains 2% casein, 10 mM Tris-citrate buffer pH 6.0 +/-0.1, 0.1% Tween 20, 0.09% Na-azide and 0.045% ProClin 300 as preservatives. The reagent is blue colour coded.

9. Plate sealing foils n°2

10. Package insert n°1

E. MATERIALS REQUIRED BUT NOT PROVIDED

- Calibrated Micropipettes (1000 ul, 100 ul and 10 ul) and disposable plastic tips.
- EIA grade water (double distilled or deionised, charcoal treated to remove oxidizing chemicals used as disinfectants).
- Timer with 60 minute range or higher. 3.
- 4. Absorbent paper tissues.
- Calibrated ELISA microplate thermostatic incubator (dry or 5. wet), set at +37°C (+/-0.5°C tolerance)..
- 6. Calibrated ELISA microwell reader with 450nm (reading) and with 620-630nm (blanking) filters.
- Calibrated ELISA microplate washer.
- 8. Vortex or similar mixing tools.

F. WARNINGS AND PRECAUTIONS

1. The kit has to be used by skilled and properly trained technical personnel only, under the supervision of a medical doctor responsible of the laboratory.

All the personnel involved in performing the assay have to wear protective laboratory clothes, talc-free gloves and glasses. The use of any sharp (needles) or cutting (blades) devices should be avoided. All the personnel involved should be trained in biosafety procedures, as recommended by the Center for Disease Control, Atlanta, U.S. and reported in the National

Doc.: INS CMVG.CE/eng	Page	3 of 9	Rev.: 5	Date: 2019/11
-----------------------	------	--------	---------	---------------

Institute of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.

All the personnel involved in sample handling should be 3. vaccinated for HBV and HAV, for which vaccines are available, safe and effective.

The laboratory environment should be controlled so as to 4. avoid contaminants such as dust or air-born microbial agents, when opening kit vials and microplates and when performing the test. Protect the Chromogen (TMB) from strong light and avoid vibration of the bench surface where the test is undertaken.

Upon receipt, store the kit at 2..8°C into a temperature 5. controlled refrigerator or cold room.

6 Do not interchange components between different lots of the kits. It is recommended that components between two kits of the same lot should not be interchanged.

Check that the reagents are clear and do not contain 7. visible heavy particles or aggregates. If not, advise the laboratory supervisor to initiate the necessary procedures for kit replacement.

cross-contamination 8 Avoid between serum/plasma samples by using disposable tips and changing them after each sample. Do not reuse disposable tips.

Avoid cross-contamination between kit reagents by using disposable tips and changing them between the use of each one. Do not reuse disposable tips.

10. Do not use the kit after the expiration date stated on the external container and internal (vials) labels. A study conducted on an opened kit did not pointed out any relevant loss of activity up to six 6 uses of the device and up to 3 months.

11. Treat all specimens as potentially infective. All human serum specimens should be handled at Biosafety Level 2, as recommended by the Center for Disease Control, Atlanta, U.S. in compliance with what reported in the Institutes of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.

The use of disposable plastic-ware is recommended in the 12. preparation of the liquid components or in transferring components into automated workstations, in order to avoid cross contamination

13. Waste produced during the use of the kit has to be discarded in compliance with national directives and laws concerning laboratory waste of chemical and biological In particular, liquid waste generated from the substances. washing procedure, from residuals of controls and from samples has to be treated as potentially infective material and inactivated Suggested procedures of inactivation are before waste. treatment with a 10% final concentration of household bleach for 16-18 hrs or heat inactivation by autoclave at 121°C for 20 min..

14. Accidental spills from samples and operations have to be adsorbed with paper tissues soaked with household bleach and then with water. Tissues should then be discarded in proper containers designated for laboratory/hospital waste.

The Sulphuric Acid is an irritant. In case of spills, wash the surface with plenty of water

16. Other waste materials generated from the use of the kit (example: tips used for samples and controls, used microplates) should be handled as potentially infective and disposed according to national directives and laws concerning laboratory wastes

G. SPECIMEN: PREPARATION AND WARNINGS

1. Blood is drawn aseptically by venepuncture and plasma or serum is prepared using standard techniques of preparation of samples for clinical laboratory analysis. No influence has been observed in the preparation of the sample with citrate, EDTA and heparin.

2. Samples have to be clearly identified with codes or names in order to avoid misinterpretation of results. Bar code labeling and electronic reading is strongly recommended.

3. Haemolysed ("red") and visibly hyperlipemic ("milky") samples have to be discarded as they could generate false results.

Samples containing residues of fibrin or heavy particles or microbial filaments and bodies should be discarded as they could give rise to false results.

4. Sera and plasma can be stored at +2°...+8°C in primary collection tubes for up to five days after collection. Do not freeze primary tubes of collection. For longer storage

periods, sera and plasma samples, carefully removed from the primary collection tube, can be stored frozen at -20°C for at least 12 months. Any frozen samples should not be frozen/thawed more than once as this may generate particles that could affect the test result.

If particles are present, centrifuge at 2.000 rpm for 20 min or

filter using 0.2-0.8u filters to clean up the sample for testing. 6. Samples whose anti-CMV IgG antibody concentration is expected to be higher than 8 IU/ml should be diluted before use, either 1:10 or 1:100 in the Calibrator 0 IU/ml. Dilutions have to be done in clean disposable tubes by diluting 50 ul of each specimen with 450 ul of Cal 0 (1:10). Then 50 ul of the 1:10 dilution are diluted with 450 ul of the Cal 0 (1:100). Mix tubes thoroughly on vortex and then proceed toward the dilution step reported in section M.

H. PREPARATION OF COMPONENTS AND WARNINGS

A study conducted on an opened kit has not pointed out any relevant loss of activity up to 6 re-uses of the device and up to 3 months.

Microplate:

Allow the microplate to reach room temperature (about 1 hr) before opening the container. Check that the desiccant has not turned dark green, indicating a defect in manufacturing. In this case, call Dia.Pro's customer service.

Unused strips have to be placed back into the aluminum pouch, with the desiccant supplied, firmly zipped and stored at +2°..8°C

After first opening, remaining strips are stable until the humidity indicator inside the desiccant bag turns from yellow to green.

Calibration Curve

Ready to use component. Mix carefully on vortex before use.

Control Serum

Add the volume of ELISA grade water, reported on the label, to the lyophilised powder; let fully dissolve and then gently mix on vortex

Note: The control after dissolution is not stable. Store frozen in aliquots at -20°C.

Wash buffer concentrate:

The whole content of the concentrated solution has to be diluted 20x with bidistilled water and mixed gently end-over-end before During preparation avoid foaming as the presence of use bubbles could impact on the efficiency of the washing cycles. Note: Once diluted, the wash solution is stable for 1 week at +2..8° C.

Enzyme conjugate:

Ready to use. Mix well on vortex before use.

Be careful not to contaminate the liquid with oxidizing chemicals. air-driven dust or microbes.

If this component has to be transferred use only plastic, possibly sterile disposable containers.

Chromogen/Substrate:

Ready to use. Mix well on vortex before use.

Be careful not to contaminate the liquid with oxidizing chemicals, air-driven dust or microbes.

Do not expose to strong illumination, oxidizing agents and metallic surfaces.

If this component has to be transferred use only plastic, possible sterile disposable container

	Doc.:	INS CMVG.CE/eng	Page	4 of 9	Rev.: 5	Date: 2019/11
--	-------	-----------------	------	--------	---------	---------------

Sample Diluent

Ready to use component. Mix carefully on vortex before use.

Sulphuric Acid:

Ready to use. Mix well on vortex before use.

Attention: Irritant (H315, H319; P280, P302+P352, P332+P313, P305+P351+P338, P337+P313, P362+P363).

Legenda:

Warning H statements:

H315 – Causes skin irritation. H319 – Causes serious eye irritation.

Precautionary P statements:

Wear protective P280 gloves/protective clothing/eye protection/face protection.

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water.

P332 + P313 - If skin irritation occurs: Get medical advice/attention.

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. **P337 + P313** – If eye irritation persists: Get medical

advice/attention.

P362 + P363 - Take off contaminated clothing and wash it before reuse.

I. INSTRUMENTS AND TOOLS USED IN COMBINATION WITH THE KIT

- 1. Micropipettes have to be calibrated to deliver the correct volume required by the assay and must be submitted to regular decontamination (household alcohol, 10% solution bleach, hospital grade disinfectants) of those parts that of could accidentally come in contact with the sample. They should also be regularly maintained in order to show a precision of 1% and a trueness of +/-2%. Decontamination of spills or residues of kit components should also be carried out regularly.
- The ELISA incubator has to be set at +37°C (tolerance of +/-2. 0.5°C) and regularly checked to ensure the correct temperature is maintained. Both dry incubators and water baths are suitable for the incubations, provided that the nstrument is validated for the incubation of ELISA tests.
- The ELISA washer is extremely important to the overall 3 performances of the assay. The washer must be carefully validated in advance, checked for the delivery of the right dispensation volume and regularly submitted to maintenance according to the manufacturer's instructions for use. In particular the washer, at the end of the daily workload, has to be extensively cleaned out of salts with deionized water. Before use, the washer has to be extensively primed with the diluted Washing Solution.

instrument weekly has to be submitted decontamination according to its manual (NaOH 0.1 M decontamination suggested).

5 washing cycles (aspiration + dispensation of 350ul/well of washing solution + 20 sec soaking = 1 cycle) are sufficient to ensure the assay with the declared performances. If soaking is not possible add one more cycle of washing.

An incorrect washing cycle or salt-blocked needles are the major cause of false positive reactions.

Incubation times have a tolerance of +5%.

The ELISA microplate reader has to be equipped with a reading filter of 450nm and with a second filter of 620-630nm, mandatory for blanking purposes. Its standard performances should be (a) bandwidth \leq 10 nm; (b) absorbance range from 0 to \geq 2.0; (c) linearity to \geq 2.0; repeatability > 1%. Blanking is carried out on the well identified in the section "Assay Procedure". The optical system of the reader has to be calibrated regularly to ensure

that the correct optical density is measured. It should be regularly maintained according to the manufacturer instructions.

- When using an ELISA automated work station, all critical 6. steps (dispensation, incubation, washing, reading, data handling) have to be carefully set, calibrated, controlled and regularly serviced in order to match the values reported in the sections "Validation of Test" and "Assay Performances". The assay protocol has to be installed in the operating system of the unit and validated as for the washer and the reader. In addition, the liquid handling part of the station (dispensation and washing) has to be validated and correctly set. Particular attention must be paid to avoid carry over by the needles used for dispensing and for washing. This must be studied and controlled to minimize the possibility of contamination of adjacent wells. The use of ELISA automated work stations is recommended when the number of samples to be tested exceed 20-30 units per run.
- 7. Dia.Pro's customer service offers support to the user in the setting and checking of instruments used in combination with the kit, in order to assure compliance with the requirements described. Support is also provided for the installation of new instruments to be used with the kit.

L. PRE ASSAY CONTROLS AND OPERATIONS

- Check the expiration date of the kit printed on the external 1. label (primary container). Do not use if expired.
- Check that the liquid components are not contaminated by visible particles or aggregates. Check that the Chromogen (TMB) is colourless or pale blue
- 3. by aspirating a small volume of it with a sterile plastic
- pipette. Check that no breakage occurred in transportation and no spillage of liquid is present inside the box (primary container). Check that the aluminium pouch, containing the microplate, is not punctured or damaged.
- 5. Dissolve the content of the lyophilised Control Serum as reported in the proper section.
- Dilute all the content of the 20x concentrated Wash Solution 6. as described above.
- Allow all the other components to reach room temperature (about 1 hr) and then mix gently on vortex all liquid reagents.
- Set the ELISA incubator at +37°C and prepare the ELISA 8. washer by priming with the diluted washing solution, according to the manufacturers instructions. Set the right number of washing cycles as reported in the specific section.
- Check that the ELISA reader is turned on or ensure it will be 9. turned on at least 20 minutes before reading.
- 10. If using an automated work station, turn on, check settings and be sure to use the right assay protocol.
- 11. Check that the micropipettes are set to the required volume.
- 12. Check that all the other equipment is available and ready to use.
- 13. In case of problems, do not proceed further with the test and advise the supervisor.

M. ASSAY PROCEDURE

The assay has to be carried out according to what reported below, taking care to maintain the same incubation time for all the samples in testing.

The kit may be used for quantitative and qualitative determinations as well.

M1. QUANTITATIVE DETERMINATION:

Automated assay:

In case the test is carried out automatically with an ELISA system, we suggest to make the instrument aspirate 1000 μI

Doc.: INS CMVG.CE/eng	Page	5 of 9	Rev.: 5	Date: 2019/11	
-----------------------	------	--------	---------	---------------	--

Sample Diluent and then 10 µl sample (1:101 dilution factor). The whole content is then dispensed into a properly defined dilution tube. Before the next sample is aspirated, needles have to be duly washed to avoid any cross-contamination among samples. When all the samples have been diluted make the instrument dispense 100 µl samples into the proper wells of the microplate.

This procedure may be carried out also in two steps of dilutions of 1:10 each (90 μI Sample Diluent + 10 μI sample) into a second dilution platform. Make then the instrument aspirate first 100 µl Sample Diluent, then 10 µl liquid from the first dilution in the platform and finally dispense the whole content in the proper well of the assay microplate.

Do not dilute Calibrators and the dissolved Control Serum as they are ready to use.

Dispense 100 µl calibrators/control in the appropriate calibration/control wells.

For the next operations follow the operative instructions reported below for the Manual Assay. It is strongly recommended to check that the time lap between

the dispensation of the first and the last sample will be calculated by the instrument and taken into consideration by delaying the first washing operation accordingly.

Manual assay:

- Dilute samples 1:101 into a properly defined dilution tube 1. (example: 1000 µl Sample Diluent + 10 µl sample). Do not dilute the Calibration Set as calibrators are ready to use. Mix carefully all the liquid components on vortex and then proceed as described below. Place the required number of microwells in the microwell
- 2 holder. Leave the A1 and B1 empty for the operation of blanking.
- Dispense 100 μI of Calibrators and 100 μI Control Serum in 3. duplicate. Then dispense 100 µl of diluted samples in each properly identified well.
- 4. Incubate the microplate for 60 min at +37°C

Important note: Strips have to be sealed with the adhesive sealing foil, supplied, only when the test is carried out manually. Do not cover strips when using ELISA automatic instruments.

- Wash the microplate with an automatic washer by 5. delivering and aspirating as reported previously (section 1.3).
- Pipette 100 µl Enzyme Conjugate into each well, except 6 A1+B1 blanking wells, and cover with the sealer. Check that this red coloured component has been dispensed in all the wells, except A1 and B1.

Important note: Be careful not to touch the plastic inner surface of the well with the tip filled with the Enzyme Conjugate. Contamination might occur.

- Incubate the microplate for 60 min at +37°C. 7.
- 8. Wash microwells as in step 5.
- Pipette 100 µl Chromogen/Substrate mixture into each well, the blank wells A1 and B1 included. Then incubate the microplate at room temperature (18-24°C) for 20 minutes

Important note: Do not expose to strong direct illumination. High background might be generated.

- 10. Pipette 100 μI Sulphuric Acid to stop the enzymatic reaction into all the wells using the same pipetting sequence as in step 9. Addition of acid will turn the positive calibrators, the control serum and the positive samples from blue to yellow.
- 11. Measure the colour intensity of the solution in each well, as described in section I.5, at 450nm filter (reading) and at 620-630nm (background subtraction, mandatory), blanking the instrument on A1 or B1 or both.

M2. QUALITATIVE DETERMINATION

If only a qualitative determination is required, proceed as described below:

Automated assay: Proceed as described in section M1.

Manual assay:

- Dilute samples 1:101 into a properly defined dilution tube (example: 1000 μ l Sample Diluent + 10 μ l sample). Do not dilute the Calibration Set as calibrators are ready to use. Mix carefully all the liquid components on vortex and then proceed as described below.
- 2. Place the required number of Microwells in the microwell
- holder. Leave A1 well empty for the operation of blanking. Dispense 100 μ l Calibrator 0 IU/ml and 100 μ l Calibrator 0.5 IU/ml in duplicate, and 100 μ l Calibrator 8 IU/ml in single. 3 Then dispense 100 µl of diluted samples in each properly identified well.
- 4. Incubate the microplate for 60 min at +37°C.

Important note: Strips have to be sealed with the adhesive sealing foil, supplied, only when the test is carried out manually. Do not cover strips when using ELISA automatic instruments.

- Wash the microplate with an automatic washer by delivering 5. and aspirating as reported previously (section I.3).
- Pipette 100 µl Enzyme Conjugate into each well, except the 6 A1 well, and cover with the sealer. Check that this red coloured component has been dispensed in all the wells, except A1.

Important note: Be careful not to touch the plastic inner surface of the well with the tip filled with the Enzyme Conjugate. Contamination might occur.

- Incubate the microplate for 60 min at +37°C.
- Wash microwells as in step 5. 8.
- Pipette 100 µl Chromogen/Substrate mixture into each well, the blank well included. Then incubate the microplate at room temperature (18-24°C) for 20 minutes.

Important note: Do not expose to strong direct illumination. High background might be generated.

- 10. Pipette 100 µl Sulphuric Acid into all the wells using the same pipetting sequence as in step 9. Addition of acid will turn the positive calibrators, the control serum and the positive samples from blue to yellow.
- Measure the colour intensity of the solution in each well, as 11. described in section I.5, at 450nm filter (reading) and at 620-630nm (background subtraction, mandatory), blanking the instrument on A1.

General Important notes:

- Ensure that no finger prints are present on the bottom of the microwell before reading. Finger prints could generate false positive results on reading.
- Reading has to be carried out just after the addition of the Stop Solution and anyway not any longer than 20 minutes after its addition. Some self oxidation of the chromogen can occur leading to high background.
- The Control Serum (CS) does not affect the test results calculation. The Control Serum may be used only when a laboratory internal quality control a laboratory internal quality control is required by the management.

Doc.:	INS CMVG.CE/eng	Page	6 of 9	Rev.: 5	Date: 2019/11
-------	-----------------	------	--------	---------	---------------

N. ASSAY SCHEME

Method	Operations
Calibrators & Control	100 µl
Samples diluted 1:101	100 µl
1 st incubation	60 min
Temperature	+37°C
Wash step	n° 5 cycles with 20" of soaking
	OR
	n° 6 cycles without soaking
Enzyme conjugate	100 µl
2 nd incubation	60 min
Temperature	+37°C
Wash step	n° 5 cycles with 20" of soaking
	OR
	n° 6 cycles without soaking
TMB/H2O2	100 µl
3 rd incubation	20 min
Temperature	r.t.
Sulphuric Acid	100 ul
Reading OD	450nm / 620-630nm

An example of dispensation scheme for Quantitative Analysis is reported below:

	Microplate											
	1	2	3	4	5	6	7	8	9	10	11	12
Α	BLK	CAL4	S 1									
В	BLK	CAL4	S 2									
С	CAL1	CAL5	S 3									
D	CAL1	CAL5	S 4									
E	CAL2	CAL6	S 5									
F	CAL2	CAL6	S 6									
G	CAL3	CS	S 7									
Н	CAL3	CS	S 8									
Lege	enda: BLK	= Blank C	AL = Ca	librat	or (CS =	Con	trol S	erum	S =	Sample	•

An example of dispensation scheme in qualitative assays is reported below:

Microplate

						-						
	1	2	3	4	5	6	7	8	9	10	11	12
Α	BLK	S 3	S 11									
В	CAL1	S 4	S 12									
С	CAL1	S 5	S 13									
D	CAL2	S 6	S 14									
Е	CAL2	S 7	S 15									
F	CAL6	S 8	S 16									
G	S 1	S 9	S 17									
Н	S 2	S 10	S 18									
1.00	anda, DI	K - Dlan		Calib	rotor	<u> </u>	Cant			6 - 6	مسماه	

Legenda: BLK = Blank CAL = Calibrator CS = Control Serum S = Sample

O. INTERNAL QUALITY CONTROL

A validation check is carried out on the controls and the calibrator any time the kit is used in order to verify whether the performances of the assay are as expected and required by the IVDD directive 98/79/EC. Control that the following data are matched:

Check	Requirements
Blank well	< 0.100 OD450nm value
Calibrator 0 IU/ml (CAL1)	< 0.150 mean OD450nm value after blanking
	coefficient of variation < 30%
Calibrator 0.5IU/ml	OD450nm > OD450nm CAL1 + 0.100
Calibrator 8 IU/ml	OD450nm > 1.000
Control Serum	2 WHO IU/ml +/-10%

If the results of the test match the requirements stated above, proceed to the next section.

If they do not, do not proceed any further and operate as follows:

Problem	Check
Blank well > 0.100 OD450nm	1. that the Chromogen/Substrate solution has not got contaminated during the assay
Calibrator 0 IU/ml > 0.150 OD450nm after blanking coefficient of variation > 30%	 that the washing procedure and the washer settings are as validated in the pre qualification study; that the proper washing solution has been used and the washer has been primed with it before use; that no mistake has been done in the assay procedure (dispensation of a positive calibrator instead of the negative one; that no contamination of the negative calibrator or of their wells has occurred due to positive samples, to spills or to the enzyme conjugate; that micropipettes haven't got contaminated with positive samples or with the enzyme conjugate that the washer needles are not blocked or partially obstructed.

Doc.:	INS CMVG.CE/eng	Page	7 of 9	Rev.: 5	Date: 2019/11

L	
Calibrator 0.5 IU/ml	1. that the procedure has been
	correctly executed;
OD450nm <	2. that no mistake has been done in
OD450nm CAL1 +	its distribution (ex.: dispensation of a
0.100	wrong calibrator instead);
	3. that the washing procedure and the
	washer settings are as validated in
	the pre qualification study;
	4. that no external contamination of
	the calibrator has occurred.
Calibrator 8 IU/ml	1. that the procedure has been
Calibrator & IU/III	
	correctly executed;
< 1.000 OD450nm	2. that no mistake has been done in
	its distribution (dispensation of a
	wrong calibrator instead) ;
	3. that the washing procedure and the
	washer settings are as validated in
	the pre qualification study;
	4. that no external contamination of
	the positive control has occurred.
Control Serum	First verify that:
	1. the procedure has been correctly
Different from	performed;
expected value	2. no mistake has occurred during its
	distribution (ex.: dispensation of a
	wrong sample);
	3. the washing procedure and the
	washer settings are correct;
	4. no external contamination of the
	standard has occurred.
	5. the Control Serum has been
	dissolved with the right volume
	reported on the label.
	If a mistake has been pointed out, the
	assay has to be repeated after
	eliminating the reason of this error.
	If no mistake has been found,
	proceed as follows:
	a) a value up to +/-20% is obtained:
	the overall Precision of the laboratory
	might not enable the test to match the
	expected value +/-10%. Report the
	problem to the Supervisor for
	acceptance or refusal of this result.
	b) a value higher than +/-20% is
	obtained: in this case the test is
	invalid and the DiaPro's customer
	service has to be called.

Should one of these problems have happened, after checking, report to the supervisor for further actions.

Important Notes:

The analysis must be done proceeding as the reading step described in the section M, point 11.


P. RESULTS

P.1 Quantitative method

If the test turns out to be valid, use for the quantitative method an approved curve fitting program to draw the calibration curve from the values obtained by reading at 450nm/620-630nm (4parameters interpolation is suggested). Then on the calibration curve calculate the concentration of anti

Then on the calibration curve calculate the concentration of anti Cytomegalovirus IgG antibody in samples.

An example of Calibration curve is reported in the next page.



Example of Calibration Curve :

Important Note:

Do not use the calibration curve above to make calculations.

P.2 Qualitative method

In the qualitative method, calculate the mean OD450nm/620-630nm values for the Calibrators 0 and 0,5 IU/ml and then check that the assay is valid.

An example of calculation is reported below (data obtained proceeding as the the reading step described in the section M, point 11).

The following data must not be used instead of real figures obtained by the user.

Calibrator 0 IU/ml: 0.035 – 0.045 OD450nm Mean Value: 0.040 OD450nm Lower than 0.150 – Accepted Calibrator 0.5 IU/ml: 0.260 – 0.280 OD450nm Mean Value: 0.270 OD450nm Higher than Cal 0 + 0.100 – Accepted Calibrator 8 IU/ml: 2.885 OD450nm Higher than 1.000 – Accepted

Q. INTERPRETATION OF RESULTS

Samples with a concentration lower than 0.5 WHO IU/ml are considered negative for anti Cytomegalovirus IgG antibody. Samples with a concentration higher than 0.5 WHO IU/ml are considered positive for anti Cytomegalovirus IgG antibody. Particular attention in the interpretation of results has to be used in the follow-up of pregnancy for an infection of Cytomegalovirus due to the risk of severe neonatal malformations.

Important notes:

- Interpretation of results should be done under the supervision of the laboratory supervisor to reduce the risk of judgment errors and misinterpretations.
- When test results are transmitted from the laboratory to another facility, attention must be paid to avoid erroneous data transfer.
- 3. In the follow-up of pregnancy for Cytomegalovirus infection a positive result (presence of IgG antibody > 0.5 IU/ml)

Doc.:	INS CMVG.CE/eng	Page	8 of 9	Rev.: 5	Date: 2019/11

should be confirmed to ruled out the risk of a false positive result and a false definition of protection.

R. PERFORMANCES

Evaluation of Performances has been conducted in accordance with the European standard.

1. Limit of detection

The limit of detection of the assay (or analytical sensitivity) has been calculated by means of the 1st proposed international standard produced by the World Health Organization (WHO) for CMV lgG.

The limit of detection has been calculated as mean OD450nm Calibrator 0 WHO IU/ml + 5 SD.

The table below reports the mean OD450nm values of this standard when diluted in negative plasma and then examined in the assav.

Mean OD450nm

WHO IU/ml	CMVG.CE Lot # 0303	CMVG.CE Lot #0203	CMVG.CE Lot # 0103
2	1.053	1.101	1.098
1	0.524	0.498	0.559
0.5	0.277	0.268	0.271
0.25	0.150	0.169	0.161
0.125	0.080	0.091	0.087
Negative	0.039	0.035	0.040

The assay shows a limit of detection far better than 0.5 WHO IU/ml; however the interpretation of results is maintained at that value in order to safely monitor pregnancy and neonatal risk.

2. Diagnostic sensitivity: The diagnostic sensitivity has been tested in an external performance evaluation study (University Hospital, Microbiology Department, Salamanca, Spain) on panels of samples classified positive by a kit US FDA approved. Positive samples from different stage of CMV infection were tested.

The value, obtained from the analysis of more than 300 specimens, has been > 98%.

In addition the seroconversion panel PT 901 produced by Boston Biomedical Inc., BBI, USA, has been tested. Results are reported below with reference to an European kit.

BBI	Panel	PTC	901
-----	-------	-----	-----

Member	CMVG.CE	BioMerieux	
ID	OD450nm	S/Co	VIDAS
01	0.071	0.2	Negative
02	0.043	0.1	Negative
03	0.057	0.2	Negative
04	0.046	0.1	Negative
05	0.086	0.3	Negative
06	1.002	3.2	Positive
07	1.442	4.6	Positive
08	1.630	5.2	Positive
09	1.770	5.6	Positive

Note: Cut-Off = 0.5 IU/ml = 0.316

3. Diagnostic specificity:

The diagnostic specificity has been determined in the same centre on panels of negative samples from not infected individuals, classified negative with a kit US FDA approved. Both plasma, derived with different standard techniques of preparation (citrate, EDTA and heparin), and sera have been used to determine the value of specificity.

Frozen specimens have been tested, as well, to check for interferences due to collection and storage. No interference was observed.

Potentially interfering samples derived from patients with different pathologies (mostly ANA, AMA and RF positive) and from pregnant women were tested.

No crossreaction was observed.

An overall value > 98% of specificity was found when examined on more than 100 specimens.

Precision:

It has been calculated on three samples, a negative, a low positive and a positive, examined in 16 replicates in three separate runs for three lots. Results are reported as follows:

CMVG.CE: lot # 0303

Calibrator 0 IU/ml (N = 16)

Mean values	1st run	2nd run	3 rd run	Average
				value
OD 450nm	0.073	0.073	0.077	0.074
Std.Deviation	0.010	0.010	0.009	0.010
CV %	13.3	14	12	13.1

Calibrator 0.5 IU/ml (N = 16)

Mean values	1st run	2nd run	3 rd run	Average
				value
OD 450nm	0.316	0.292	0.309	0.306
Std.Deviation	0.027	0.015	0.020	0.020
CV %	8.4	5.1	6.3	6.6

Calibrator 8 IU/ml (N = 16)

Mean values	1st run	2nd run	3 rd run	Average
				value
OD 450nm	3.262	3.137	3.210	3.203
Std.Deviation	0.126	0.065	0.147	0.113
CV %	3.9	2.1	4.6	3.5

CMVG.CE: lot # 0203

Calibrator 0 IU/mI (N = 16)						
Mean values	1st run	2nd run	3 rd run	Average		
				value		
OD 450nm	0.058	0.060	0.063	0.061		
Std.Deviation	0.005	0.005	0.005	0.005		
CV %	8.8	7.9	8.6	8.4		

Calibrator 0.5 IU/ml (N = 16)

Mean values	1st run	2nd run	3 rd run	Average value
OD 450nm	0.299	0.297	0.300	0.299
Std.Deviation	0.012	0.007	0.011	0.010
CV %	3.9	2.5	3.6	3.3

Calibrator 8 IU/ml (N = 16)

Mean values	1st run	2nd run	3 rd run	Average value
OD 450nm	3.124	3.062	3.094	3.093
Std.Deviation	0.051	0.068	0.057	0.059
CV %	1.6	2.2	1.9	1.9

CMVG.CE: lot # 0103

Calibrator 0 IU/ml (N = 16)						
Mean values	1st run	2nd run	3 rd run	Average		
				value		
OD 450nm	0.064	0.062	0.067	0.064		
Std.Deviation	0.005	0.005	0.006	0.005		
CV %	7.9	8.3	8.2	8.1		

Calibrator 0.5 IU/ml (N = 16)

Mean values	1st run	2nd run	3 rd run	Average value
OD 450nm	0.314	0.300	0.296	0.303
Std.Deviation	0.031	0.019	0.012	0.021
CV %	10.0	6.5	4.0	6.8

Doc.:	INS CMVG.CE/eng	Page	9 of 9	Rev.: 5	Date: 2019/11

Calibrator 8 IU/ml (N = 16)								
Mean values	1st run	2nd run	3 rd run	Average value				
OD 450nm	2.729	2.688	2.700	2.705				
Std.Deviation	0.109	0.067	0.109	0.095				
CV %	4.0	2.5	4.0	3.5				

The variability shown in the tables above did not result in sample misclassification.

5. Accuracy The assay accuracy has been checked by the dilution and recovery tests. Any "hook effect", underestimation likely to happen at high doses of analyte, was ruled.

Important note:

The performance data have been obtained proceeding as the reading step described in the section M, point 11.

S. LIMITATIONS OF THE PROCEDURE

Bacterial contamination or heat inactivation of the specimen may affect the absorbance values of the samples with consequent alteration of the level of the analyte.

Frozen samples containing fibrin particles or aggregates after thawing may generate some false results.

This test is suitable only for testing single samples and not pooled ones.

Diagnosis of an infectious disease should not be established on the basis of a single test result. The patient's clinical history, symptomatology, as well as other diagnostic data should be considered.

REFERENCES

- 1. Engvall E. and Perlmann P.. J.Immunochemistry 8: 871-874, 1971
- Engvall E. and Perlmann P.. J.Immunol.. 109: 129-135, 2 1971
- Remington J.S. and Klein J.O.. (1996) In "Infectious diseases of fetus and newborn infant". Sanders, 3.
- Philadelphia, London, Toronto. Volk W.A. (1982) In "essential of Medical Microbiology". 2nd ed., pp 729, G.B. Lippincott Co. Philadelphia, New York, S.Josè, Toronto. 4.
- 5. Leinikki P.O. et al.. J.Clin.Microbiol.. 8:418, 1978
- 6. Piroid E. et al.. Révue Méd.Vet.. 131:25, 1980.
- 7. Vaheri A. et al.. J.Med.Virol.. 5:171, 1980.
- Vejtorp M. et al.. Acta Path.Microbiol.Scand.. 88:349, 1980. 8.
- Voller A. et al.. Brit.J.Exp.Pathol.. 56:338, 1975 9.

All the IVD Products manufactured by the company are under the control of a certified Quality Management System approved by an EC Notified Body. Each lot is submitted to a quality control and released into the market only if conforming with the EC technical specifications and acceptance criteria.

Manufacturer: Dia.Pro. Diagnostic Bioprobes Srl.

Via G. Carducci n° 27 – Sesto San Giovanni (MI) - Italy

